Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
APP- possible entry today as earnings are released after market is closed today.
KOG- link to earnings. They missed estimates by .01 but had record numbers in almost all aspects of their business.
http://finance.yahoo.com/news/Kodiak-Oil-Gas-Corp-Reports-prnews-575422614.html?x=0
Highlights Include:
* RECORD PROVED RESERVES TOTAL 4.5 MMBOE
* RECORD ANNUAL PRODUCTION OF 219 MBOE
* CURRENT PRODUCTION ~1,500 BOEPD
* RECORD ANNUAL AND QUARTERLY OIL & GAS SALES OF $11.3 MM AND $4.8 MM, RESPECTIVELY
* RECORD 2009 OPERATING CASH FLOW OF $9.4 MM
* STRONGEST SHORT LATERAL WELLS DRILLED TO DATE
KOG 2.84 x 2.85 now!! New HOD and approaching 52-week high of 2.94!
KOG- higher highs each day. Seems like it's setting itself up for a very nice run going into earnings. If they beat estimates this could easily hit 3.50 or higher, imo. Good luck to those that jumped in with me. I'm in at 2.65 a share, up .10 currently.
KOG- new HOD!! 2.73 x 2.74 and it doesn't seem to be slowing down. Major buying with earnings this Thursday says there is a lot of confidence that they meet or beat estimates.
Unfortunately I didn't but I'm glad for you. I hope it keeps going.
Right now, I'm looking at taking a position in KOG, SBCF, ADLR, or YTEC. Also, I'm probably going to eliminate my other two positions to raise purchasing power.
ANO, PM $1.48.
hopefully u did.
gl
APP and KOG on watch as earnings are released next week on the 11th.
ANPI- battle for direction today. Buys start coming in and then off set by sells. Could be accumulation. Found this on another board and hopefully the company will elaborate on it today or next week.
03/03/2010
@03:30PM
10-00359-8M1
HAEMACURE CORPORATION
Atty:CHARLES A. POSTLER
Trustee:UNITED STATES TRUSTEE - TPA
1 - AUCTION/SALE
2 - MOTION FOR ORDER AUTHORIZING THE SALE OF SUBSTANTIALLY ALL OF ITS ASSETS TO ANGIOTECH PHARMACEUTICALS, INC. PURSUANT TO 11 U.S.C. SECTION 363, FREE AND CLEAR OF ALL LIENS, CLAIMS AND ENCUMBRANCES BY THE DEBTOR, DOC. #60
3 - MOTION FOR AUTHORITY TO ASSUME AND/OR ASSIGN CERTAIN EXECUTORY CONTRACTS AND UNEXPIRED LEASES TO ANGIOTECH PHARMACEUTICALS, INC. FREE AND CLEAR OF ALL LIENS, CLAIMS AND ENCUMBRANCES BY THE DEBTOR, DOC. #61
4 - EMERGENCY MOTION FOR ORDER AUTHORIZING (A) THE MAINTENANCE AND USE OF EXISTING BANK ACCOUNTS, (B) THE CONTINUED USE OF EXISTING BUSINESS FORMS, AND (C) THE WAIVER OF INVESTMENT GUIDELINES SET FORTH IN SECTION 345 OF THE BANKRUPTCY CODE BY THE DEBTOR, DOC. #14
(CONT'D FROM 1/28/10 AND 2/11/10))
5 - EMERGENCY MOTION FOR ENTRY OF AN ORDER DETERMINING THAT CERTAIN EQUIPMENT LOCATED AT ITS SARASOTA FACILITY CONSTITUTES PROPERTY OF THE ESTATE BY THE DEBTOR, DOC. #68, AND PRELIMINARY RESPONSE BY CREDITOR EXPORTKREDITNAMNDEN (EKN), SWEDISH EXPORT CREDITS GUARANTEE BOARD, DOC. #71, WITH MOTION TO SHORTEN TIME FOR DISCOVERY
***OBJECTION TO ITEM 2 AND 5 BY CREDITOR EXPORTKREDITNAMNDEN (EKN), SWEDISH EXPORT CREDITS GUARANTEE BOARD, DOC. #73***
ANPI- CC was a pretty good. They obviously missed estimates, but stated excellent achievements. One product, Quill, which is a newer product for them has now achieved #3 in the market and they anticipate that it will take over the #2 spot in market share
. This would make the product generate over $100 million a year. Also, the fear of them doing a stock offering seems to be off the table for now as they are generating enough income to keep their payments in check. They stated that restructuring their debt at lower rates is very possible. Lastly, they plan on launching multiple new products this year which would generate more income.
To sum it up, they believe their market has bottomed and they believe they will see revenues increase quarter over quarter.
One thing I forgot to mention was they increased cash on hand by $3.5 million all while paying off about $8 million in debt.
PIP- building a nice base here as it seems to be settling in after that quick pop. Close over $2 would be huge for tomorrow, imo.
PIP
Annapolis company surges ahead with anthrax vaccine
PharmAthene's $78 million government contract extension creates 30 local jobs
By ELISHA SAUERS, Staff Writer
Published 02/28/10
About a week ago, the FBI closed its investigation on the 2001 anthrax-contaminated letters case, which has fueled many skeptics' distrust of the agency, and perhaps even more paranoia about the illusive biological weapon.
And just five days after, an Annapolis-based company, which is clinically testing a second-generation anthrax vaccine, was awarded an extension on a government contract to further its development - with the hope that its product could eventually prevent more unnecessary civilian deaths as the result of another anthrax attack.
The nation's Biomedical Advanced Research and Development Authority granted the company an additional $78.4 million, officials announced last week.
PharmAthene, a biodefense firm whose headquarters are located downtown at One Park Place, is one of possibly just three companies in the world working on a more advanced vaccine, said David P. Wright, the company's president and chief executive officer.
Two of those companies are based in Maryland. Emergent Biosolutions, a biodefense company based in Rockville, is in early development stages of a second-generation vaccine.
For the company, this funding was crucial, Wright said. PharmAthene forsome time had been vying for a $500 million government contract that originally was solicited for both development and procurement. But a few months ago, the government decided to separate contracts for development and procurement. The company's existing funding may have dried up in about a year's time without the infusion.
"This (additional funding) removed any lag in development time that could occur from the previous cancellation of the (request for proposal), and it allows us to continue moving forward without missing a step much," he said.
In anticipation of the contract's extension, PharmAthene hired 30 more employees in the past eight months, increasing the Annapolis staff from 50 to 80 workers.
The next move for the firm, Wright said, is to obtain another contract of about $150 million for the procurement stage of the vaccine, for which PharmAthene submitted a white paper at the beginning of the month. That could be awarded as early as the fourth quarter of this year.
Without that contract, Wright said the company still would survive, focusing on contracts already committed to some of PharmAthene's other products, but he said he's confident the government will continue supporting the vaccine's progress.
The government already has committed about $213 million to Pharmathene for the vaccine.
"I don't mean to be a fearmonger, but when you study this issue, anthrax is easily made, it's found in the soil all throughout the U.S., so it's not a matter of sneaking it in the country," Wright said. "You don't need 3,000 labs to make this - you can basically make this in a high school lab with equipment you can buy off the Internet."
Wright added that a gallon-sized plastic baggy of anthrax could kill more than 200,000 people.
Michael Greenberger, the founder and director of the University of Maryland's Center for Health and Homeland Security in Baltimore, said this isn't hype.
"We went through a phase sometime after Sept. 11 where people forgot about terrorism as a threat," he said.
Of the people exposed to anthrax-laced mailed in 2001, five victims died. And the government spent hundreds of millions of dollars in the clean-up of the facilities, according to documents.
A recent "report card" issued by the bipartisan Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism gave the nation an "F" in preparedness for a biological attack. The commission, led by former U.S. senators Bob Graham, D-Fla., and Jim Talent, R-Mont., stated in January that "it is more likely than not" that a weapon of mass destruction will be used somewhere in the world in the next three years.
"Nearly a decade after September 11, 2001, one year after our original report, and one month after the Christmas Day bombing attempt, the United States is failing to address several urgent threats, especially bioterrorism," Graham said in a statement. "Each of the last three Administrations has been slow to recognize and respond to the biothreat. But we no longer have the luxury of a slow learning curve, when we know al Qaeda is interested in bioweapons."
Greenberger said he believes the commission's recent remarks were intended as a wake-up call to Congress, the current administration and even civilians.
"The point is we're here with the country running huge deficits, especially because of the financial bailout, but this is an important effort (to fund)," he said. "The result is if you have an effective vaccine, it makes the weapon insignificant. And who knows - there could be a time when we'd all be vaccinated for the current biopathogen."
PharmAthene's vaccine, called SparVax, is a treatment that would come in the form of three doses over a 60-day period, said Stacey Jurchison, a spokeswoman for the company.
And that's more efficient and cost-effective than the first-generation vaccine the Food and Drug Administration licensed in the 1970s that required five doses over 18 months. A course of treatment with the currently available vaccine costs about $125, Jurchison said, but if SparVax is approved for procurement, it would cost just $45 a treatment.
Jurchison also underscores that the vaccines procured for the national stockpile are intended for civilians, not military personnel, which has its own vaccine market.
So far, the company has conducted clinical trials involving 770 people.
PIP- article from the beginning of this month. I would imagine a response should be coming soon.
PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
ANNAPOLIS, Md., Feb. 1 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has submitted a White Paper in response to the Broad Agency Announcement (Solicitation Number: BAA-BARDA-09-34) issued by the Biomedical Advanced Research and Development Authority (BARDA) for the Advanced Research and Development of Chemical, Biological, Radiological and Nuclear Medical Countermeasures. In December 2009, this BAA was specially modified and extended to accommodate rPA-related submissions.
David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "In consultation with BARDA, today PharmAthene submitted a White Paper for advanced development of SparVax™ in response to the BAA. If BARDA finds our submission acceptable, a formal proposal will be requested. We believe that, if awarded, funding provided under this BAA, along with potential additional funding under our existing contract with BARDA, will be sufficient to advance SparVax™ to a stage where it will be eligible for consideration for a Project BioShield procurement contract."
"There has been widespread acknowledgement across the scientific community of the need for a next-generation anthrax vaccine that offers the potential for improved safety, convenience and cost-effectiveness. SparVax™ is the leading rPA-based vaccine and is well positioned to meet these requirements. We look forward to continuing our work with the government to develop the necessary medical countermeasure to successfully deter or quickly respond to a biologic attack and save American lives," continued Mr. Wright.
About SparVax™
SparVax™ is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection. This product candidate employs modern vaccine technology to provide a highly purified and well characterized modern vaccine for intended use by the military and civilian Strategic National Stockpile. Phase I and Phase II clinical trials involving more than 750 healthy human subjects have been completed and showed that SparVax™ appears to be well tolerated and induces an immune response in humans. These studies suggest that three doses of SparVax™, administered several weeks apart, should be sufficient to induce protective immunity. In non-clinical studies SparVax™ has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain. The clinical and non-clinical studies for SparVax™ have been carried out under contracts with the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
* SparVax™ -- a second generation recombinant protective antigen (rPA) anthrax vaccine
* Third generation rPA anthrax vaccine
* Valortim® -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
* Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
For more information about PharmAthene, please visit www.PharmAthene.com.
I have seen it in the past but haven't watched it recently. I'll put it on my list, thanks. Keep an eye on PIP. I think more developments are to come with grants.
PIP- bought some based on this:
PharmAthene Awarded up to Additional $78.4 Million Under Existing Contract for Advanced Development of SparVax(TM) Anthrax Vaccine
7:00a ET February 23, 2010 (PR NewsWire)
PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax(TM), a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile (SNS).
"We are pleased to be awarded additional development funding for our SparVax(TM) anthrax vaccine program, which may offer a promising improved alternative to existing anthrax vaccine options," commented David P. Wright, President and Chief Executive Officer. "There is widespread acknowledgement among various government agencies that the United States must develop and stockpile a second generation anthrax vaccine employing modern vaccine technology that offers the potential for improved safety, convenience and enhanced cost effectiveness. New and improved anthrax vaccines, based on modern state-of-the-art recombinant vaccine technology, incorporate significant product development and technological advancements and ultimately may provide meaningful health and economic advantages."
In addition to the funding announced today, on February 1, 2010 PharmAthene also submitted a White Paper seeking further development funding for SparVax(TM), in response to a Broad Agency Announcement (Solicitation Number: BAA-BARDA-09-34).
"We believe that, if awarded, funding provided under the BAA, along with the additional funding announced today, could be sufficient to advance SparVax(TM) to a stage where it will be eligible for consideration for a Project BioShield procurement contract," said Mr. Wright.
SparVax(TM) is a highly purified recombinant protective antigen vaccine being developed for pre and post exposure protection against anthrax infection. Phase I and Phase II clinical trials involving 770 healthy human subjects have been completed and demonstrated that SparVax(TM) appears to be well tolerated and immunogenic in humans. These studies suggest that three doses of SparVax(TM), administered over a 56 day period, are sufficient to induce protective immunity. The vaccination regimen for the currently licensed anthrax vaccine, BioThrax(R), requires five doses over a period of eighteen months.
The contract modification, which is effective February 22, 2010 and extends until December 31, 2012, provides for up to $61 million during a "base period" of performance with options for an additional $17 million on a cost reimbursement plus fixed fee basis in additional advanced development funding for SparVax(TM). Provided that certain milestones are achieved, and that all contract options and extensions are exercised by the government, the contract has a total potential value of $78.4 million. The activities outlined under the contract modification are designed to continue existing development activities already under contract (HHSO100200900103C). The modification will include non-clinical safety and efficacy studies, assay development and qualification, and process scale up and validation.
"PharmAthene has a strong track record of successfully collaborating with a number of U.S. government agencies, including, the National Institutes of Health (NIH), BARDA, the United States Army Medical Research Institute for Infectious Diseases, and the Department of Defense, to advance the development of our biodefense product portfolio to address biological and chemical threats and preserve the security and well-being of our military personnel and citizens. We are deeply committed to providing improved medical countermeasures for anthrax, which is considered to be the number one biological threat facing the Nation. We applaud President Obama's renewed commitment to protecting our Nation against the threat of bioterrorism and look forward to continuing our work with the government. It is our shared goal to develop the medical countermeasures necessary to successfully deter or quickly respond to a biologic attack and save American lives," said Mr. Wright.
Including the additional funding announced today, PharmAthene's SparVax(TM) program has been awarded funding commitments from the U.S. government totaling up to $213.2 million.
The rPA contract modification was announced via a Special Notice (Solicitation Number: HHSO100200900103C) rPA Anthrax Vaccine Advance Development, issued by HHS on December 29, 2009. The original development contract for rPA vaccine (N01-Al-30052) was issued in 2003 and transferred to BARDA on April 1, 2009.
SBIB, Sterling Bancshares Announces $80 Million Common Stock Offering
http://finance.yahoo.com/news/Sterling-Banc
shares-Announces-prnews-920952168.html?x=0&.v=1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46991834
PALM- watching for a bottom here.
BRCD- seems to be bouncing off it's low.
NXG- trying to move back up but it seems to me that someone is trying to accumulate shares down at this level.
EGY- watching for possible entry.
SBIB- looking for a possible entry maybe after offering is complete. This bank is based in Houston, TX.
I usually only trade then, but there r times that i hold for 2 days.
call you broker if u need more info.
imo, try to learn more about shorting, and paper trade before u u commit capital.
I learned some from this guy
http://www.timothysykes.com/
info.
http://www.investopedia.com/university/shortselling/shortselling1.asp
I was thinking about it. I do tend to find some stocks that they post on there that are worth while but I really have to sift through. Trade2much was a good poster and we both were making each other money with our picks but I haven't seen him in a while.
What stocks do you think would be a good short? I have some money clearing up on Friday and might be looking to get into that. Also, what are the stipulations with it? For example, let's say I short 1000 shares of F. How many days does one usually have until they have to cover? Also, let's say it drops 20% in 1 day, could I cover in one day and take my 20% and run? TIA
FLOL, I agree with u 100%. U actually lose money if u buy into their BS, unless u short really PUMP stocks (they fall the fastest).
I only watch and play my own stocks.
Try shorting
Watch precious metal stocks. The prices on the metals are turning back and heading North now. Platinum is up and Gold is almost green as well down 1.9 from 8.5 at open of market.
No I don't follow them. The article came up under Yahoo news. IMO, almost everyone you run into is a pumper. Even people on this site. I like AF's board and post regularly on there, but it's mostly people pumping their stocks they are in. Most do not post any information to back it up about the company but only that the company is going to fly. Matt (on there) kept saying for weeks that "today was the day WAVE flys". I take it all with a grain of salt until I look into the company and try and found out what they like about it. A lot of the penny stocks they pump on the board are very high risk and some do take off but some quickly fall back after a few days and are usually BK or RS candidates.
Sorry for the long rant about your question. I think the first 2 sentences answered your question. BTW, the market is killing all stocks today and it sucks!
u follow these FOOLS?
imo, bunch of pumpers.
NXG- seems to be a lot of accumulation this past couple days. I have a feeling tomorrow is the day we go green.
NXG- given 4 stars on Motley fool by their investors community.
http://www.fool.com/retirement/general/2010/02/24/4-star-stocks-poised-to-pop-northgate-minerals.aspx
CPST- out as it doesn't look like they will complete all of the shares for the offering.
PALM- on watch for a short squeeze. Latest numbers I saw were 75% of the float is short.
Thanks buddy, I appreciate it. I usually only go by the 1yr chart most of the time to identify whether or not the chart is confirming an up or down trend line and when a stock has hit bottom.
Augusta gave me this format and it's the only one I have to post. I usually go by Yahoo! charts when making a decision. If you have better charts for me to use please PM them to me. Thanks!
Why do u use a weekly chart?
R U planning on holding for months.
gl
XTXI should real up to 10 any time with earnings and forward guidance I expect will be great.
Batterymarch Financial Management Inc Institution 46,871 added XTXI as a new holding.
FCEL- I'm putting a short term target of $3.25 on this one and if it breaks through that with ease $3.50 would be the next target on tap, imo.
President's day, what a lame holiday for the market to be closed on! Looking forward to Tuesday!
EGY- apparently they start drilling at the beginning of March (3 wells). This is taken directly from their website: "DRILLING UPDATE - The jack-up drilling rig "Sapphire Driller" will go on hire to VAALCO on February 18th and commence drilling in early March".
http://www.vaalco.com/
Hey now! Thanks for stopping by my board. I have created this board for a few different reasons: To share ideas about stocks that are undervalued and have great short term and long term value, to identify sectors that are about to be hot before they heat up, and most of all to have some fun while doing all this.
Please no pinksheet or OTCBB stocks on this board. Also, any person who participates on this board please do your own DD and invest at your own risk. Any stock posted here is not necessarily a recommendation but the opinion of the poster. PLEASE, research and make your own final decisions on whether the investment is right for you.
Current play(s):
[chart]stockcharts.com/c-sc/sc?s=CBAK&p=W&yr=2&mn=3&dy=0&i=p45159707839&r=8874[/chart]
[chart]stockcharts.com/c-sc/sc?s=CBAK&p=D&yr=0&mn=4&dy=0&i=p23001212636&r=4353[/chart]
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |